NASDAQ: VAXX - Vaxxinity, Inc.

Yield per half year: -99.93%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Vaxxinity, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Vaxxinity, Inc.

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States.

more details
The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that targets toxic forms of aggregated a-synuclein in the brain to fight Parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy that is in phase 1 clinical trial; and VXX-301, an anti-tau product candidate for various neurodegenerative conditions, including AD. It is also developing UB-313 that targets calcitonin gene-related peptide to fight migraines; VXX-401 that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; and UB-612 for neutralizing the SARS-CoV-2 virus, which is in phase 3 clinical trial. Vaxxinity, Inc. was founded in 2014 and is headquartered in Merritt Island, Florida.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-11-11
ISIN US92244V1044
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.vaxxinity.com
Цена ао 0.65
Change price per day: -33.33% (0.0003)
Change price per week: -33.33% (0.0003)
Change price per month: +100% (0.0001)
Change price per 3 month: -99% (0.02)
Change price per half year: -99.93% (0.2739)
Change price per year: -99.98% (0.85)
Change price per 3 year: -100% (6.56)
Change price per 5 year: 0% (0.0002)
Change price per 10 year: 0% (0.0002)
Change price per year to date: +100% (0.0001)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 9.72 1
P/E 0 0
EV/EBITDA -2.51 0
Total: 2.63

Efficiency

Title Value Grade
ROA, % -128.37 0
ROE, % -424.6 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.2706 10
Total: 9.6

Growth impulse

Title Value Grade
Yield Revenue, % -100.18 0
Yield Ebitda, % -99.59 0
Yield EPS, % 294.77 10
Total: 4
More

Institutions Volume Share, %
Prime Movers Lab, LLC 15744167 13.95
Adage Capital Partners GP L.L.C. 3000000 2.66
Blackrock Inc. 2526951 2.24
Vanguard Group Inc 2377385 2.11
State Street Corporation 832473 0.74
Geode Capital Management, LLC 829802 0.74
Bank of America Corporation 499557 0.44
Northern Trust Corporation 351812 0.31
Creative Planning 278646 0.25
Pathstone Family Office, LLC 153846 0.14



Head Job title Payment Year of birth
Mr. Louis Garfield Reese IV Co-Founder & Executive Chairman of the Board 83.28k 1982 (43 years)
Ms. Mei Mei Hu J.D. Co-Founder, President, CEO & Director 551.73k 1983 (42 years)
Mr. Jason Pesile CPA, M.B.A. Chief Accounting Officer N/A 1973 (52 years)
Ms. Sumita Ray J.D. Chief Legal, Compliance & Administrative Officer and Corporate Secretary N/A 1974 (51 year)
Mr. Mark Joinnides MSE Chief of Staff N/A
Dr. Jean-Cosme Dodart Ph.D. Chief Scientific Officer N/A
Dr. Manal Morsy M.B.A., M.D., PH.D. Chief Regulatory Officer

Address: United States, Merritt Island. FL, 505 Odyssey Way - open in Google maps, open in Yandex maps
Website: https://www.vaxxinity.com